FDA Accepts Aricept® Patch (Donepezil Transdermal System) NDA For Review
Links shared publicly online about this topic.
- 864total visits
FDA Accepts Aricept® Patch (Donepezil Transdermal System) NDA For Review
View full resource at medicalnewstoday.com
Tags: Alzheimer's Disease Medication, Drug, Pharma, Stress Management, FDA, Aricept
Most Recently Shared on September 18, 2010 at 4:05 pm By:
FDA Accepts Aricept® Patch (Donepezil Transdermal System) NDA For Review http://mnt.to/3JZZ #pharma #pharmaceutical
Also Shared By:
New rheumatoid arthritis pill tofacitinib backed by FDA panel - HealthPop - CBS News
cbsnews.com — “Pill provides alternative to injection therapies; FDA has until August to accept or reject the panel's recommendation Read more by CBS News Staff on CBS News' HealthPop.” View full resource at cbsnews.com
Most Recently Shared on May 10, 2012 at 6:32 pm By:
Arthritis OW Active Health Library and OW Health
New rheumatoid arthritis pill tofacitinib backed by FDA panel: Pill provides alternative to injection therapies;... http://t.co/dtyLmsf4
The 23-mg Donepezil Dilemma - Journal Watch Neurology
neurology.jwatch.org — “Four months ahead of an expired patent on the acetylcholinesterase inhibitor donepezil's 5-mg and 10-mg dosages, the FDA approved a new 23-mg formulation for the treatment of moderate-to-severe Alzheimer disease (AD). This decision extended the . . .” View full resource at neurology.jwatch.org
Most Recently Shared on April 18, 2012 at 12:57 pm By:
Jennie Byrne MD PhD Doctor, Psychiatrist, Physician, and PhD
Was data for 23mg dose of donepezil (aricept) misleading? http://t.co/I8SW0Ui4
2 medical experts criticize FDA approval of high-dose Aricept - Related Stories - Hospice and Palliative Medicine SmartBrief
smartbrief.com — “The FDA's authorization of a higher dose of Aricept, an Alzheimer's disease drug marketed by Eisai and Pfizer, went against reviewers' advice and regulatory standard, Steven Woloshin and Lisa Schwartz of Dartmouth College wrote in BMJ. They said 23-milligram Aricept did not significantly improve co…” View full resource at smartbrief.com
Most Recently Shared on March 28, 2012 at 9:06 pm By:
Lionel Lim Internist, Geriatrician, Physician, and Doctor
2 medical experts criticize FDA approval of high-dose Aricept http://t.co/2ThotsPL
Higher dose of Alzheimer's drug approved despite FDA warnings, report shows - McKnight's Long Term Care News
mcknights.com — “Makers of the Alzheimer's drug Aricept released a higher dosage version of the medication despite concerns about side effects and reduced efficacy, a study reports.” View full resource at mcknights.com
Most Recently Shared on March 26, 2012 at 11:03 am By:
Alzheimer's Reading Room is the number one source of life news for the entire Alzheimer's community. Our goal is to Educate, sometimes Entertain, and Empower Alzheimers caregivers and their families worldwide.
" /> Alzheimer's Reading Room Health Advocate
Higher dose of Alzheimer's drug approved despite FDA warnings, report shows http://t.co/wZ7IlICq #alzheimer's #news
FDA Approved Higher Aricept Dose Despite Warning // Pharmalot
pharmalot.com — “FDA Approved Higher Aricept Dose Despite Warning // Pharmalot” View full resource at pharmalot.com
Most Recently Shared on March 23, 2012 at 1:01 pm By:
FDA Approved Higher Aricept Dose Despite Warning http://t.co/iCjj0VNL
Experts challenge FDA over approval for new dose of Alzheimer's drug | Science Codex
sciencecodex.com — “Approval for a new dose of a best-selling Alzheimer's drug "breached the FDA's own regulatory standard" and has led to "incomplete and distorted messages" about the drug, warn experts on bmj.com today. In the first of a new occasional” View full resource at sciencecodex.com
Most Recently Shared on March 23, 2012 at 11:58 am By:
Sara Stein MD Doctor, Psychiatrist, and Physician
#Dementia Pharma at its worst again, distorted advertising on Aricept to get you buying the new name brand version... http://t.co/puM4CgEj
How the FDA forgot the evidence: the case of donepezil 23 mg | BMJ
bmj.com — “NotesCite this as: BMJ 2012;344:e1086” View full resource at bmj.com
Most Recently Shared on March 23, 2012 at 8:44 am By:
Trish Groves Health Communicator
Donepezil (Aricept 23) dosage was approved despite warning: http://t.co/fly5xU7T #BMJ "Not so story" http://t.co/hNurZO9A
NYT: Drug Dosage Was Approved Despi
mobile.nytimes.com — “The Alzheimer's drug Aricept 23 was set to lose its patent, but its makers received approval for a higher dosage that extended their exclusivity.” View full resource at mobile.nytimes.com
Most Recently Shared on March 23, 2012 at 4:31 am By:
HospiScript Services Health Organization
Aricept 23mg-should it have been approved by the FDA? http://t.co/lqotcxp1 #hpm #hospice
Why Adjust The Dosage on A Useless Drug? | GoozNews
gooznews.com — “Professors Lisa Schwartz and Steven Woloshin of the Center for Medicine and the Media at The Dartmouth Institute for Health Policy and Clinical Practice ar...” View full resource at gooznews.com
Most Recently Shared on March 22, 2012 at 7:54 pm By:
elaine schattner Oncologist, Hematologist, Physician, Doctor, and Internist
Excellent points here, re: FDA, Aricept for Alzheimer's, ads...MT @bacigalupe: Why Adjust The Dosage on A Useless Drug? http://t.co/WAh42fH2
PaxVax announces FDA acceptance of IND for PXVX-0200 cholera vaccine
news-medical.net — “PaxVax Corporation, developer of innovative and socially responsible oral vaccines against infectious diseases, announced that the U.S. Food and Drug Administration (FDA) has accepted its investigational new drug (IND) application for its single-dose oral cholera vaccine, clearing the way to begin clinical trials. The company intends to begin Phase 3 trials later this year.” View full resource at news-medical.net
Most Recently Shared on March 19, 2012 at 1:12 pm By:
Bird Flu News: PaxVax announces FDA acceptance of IND for PXVX-0200 cholera vaccine: PaxVax Corporation, develop... http://t.co/vN7utz5a
FDA Accepts PaxVax’s IND for Single-Dose Oral Cholera Vaccine - Yahoo! Finance
finance.yahoo.com — “From Yahoo! Finance: PaxVax Corporation, developer of innovative and socially responsible oral vaccines against infectious diseases, announced that the U.S. Food and Drug Administration has accepted its investigational new drug application for its single-dose oral cholera vaccine, clearing the way to begin clinical trials.” View full resource at finance.yahoo.com
Most Recently Shared on March 19, 2012 at 1:03 pm By:
FDA Accepts PaxVax’s IND for Single-Dose Oral Cholera Vaccine: PaxVax Corporation, developer of innovative and s... http://t.co/S88mL9v2
FDA accepts Cornerstone's metabolic disorder drug application | Reuters
reuters.com — “(Reuters) - Cornerstone Therapeutics said U.S. health regulators have accepted the specialty pharmaceutical company's marketing application for its drug to treat low blood sodium levels.The U.S. Food” View full resource at reuters.com
Most Recently Shared on March 13, 2012 at 2:31 pm By:
FDA accepts Cornerstone's metabolic disorder drug application http://t.co/E9RAT3x0
FDA accepts Cornerstone's metabolic disorder drug application | Reuters
reuters.com — “(Reuters) - Cornerstone Therapeutics said U.S. health regulators have accepted the specialty pharmaceutical company's marketing application for its drug to treat low blood sodium levels.The U.S. Food” View full resource at reuters.com
Most Recently Shared on March 13, 2012 at 2:30 pm By:
FDA accepts Cornerstone's metabolic disorder drug application http://t.co/dpCVRYK7
Plethora Solutions - FDA Accept Phase II ( PSD597) - Yahoo! Finance UK
uk.finance.yahoo.com — “Read 'Plethora Solutions - FDA Accept Phase II ( PSD597)' on Yahoo! Finance UK. For Immediate Release 2 March 2006 PLETHORA SOLUTIONS HOLDINGS PLC FDA Acceptance for Phase II Clinical Trial with PSD597 Plethora Solutions Holdings PLC ("Plethora" or the "Company", ...” View full resource at uk.finance.yahoo.com
Most Recently Shared on February 26, 2012 at 10:59 am By:
Plethora Solutions - FDA Accept Phase II ( PSD597): For Immediate Release 2 March 2006 PLETHORA SOLUTIONS HOLDIN... http://t.co/D7uOdHPj
NDA Accepted for Tafamidis Meglumine for Transthyretin Familial Amyloid Polyneuropathy (TTR-FAP) - MPR
empr.com — “Pfizer Inc. announced that the FDA has accepted its New Drug Application (NDA) for tafamidis meglumine for the treatment of Transthyretin Familial Amyloid Polyneuropathy (TTR-FAP).” View full resource at empr.com
Most Recently Shared on February 15, 2012 at 3:55 pm By:
NDA Accepted for Tafamidis Meglumine for Transthyretin Familial Amyloid Polyneuropathy (TTR-FAP) http://t.co/hltLvmxI #neurodegenerative
Advertisement
MNT Stress News
@mnt_stress
FDA Accepts Aricept® Patch (Donepezil Transdermal System) NDA For Review http://mnt.to/3JZZ #stress
1 year ago...